LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. A warning letter posted Tuesday by the Food and Drug ...
The diabetes tech firm tailored its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin. The device is similar to existing prescription CGMs. Users pair the ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The partners will integrate Dexcom’s glucose sensors and ...
Zacks.com on MSN
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...
DexCom, Inc. DXCM announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...
DexCom is handing over shares in itself to Google as part of a new blood glucose monitoring collaboration. Improving care There are 387 million diabetic people worldwide and that number is estimated ...
Covering the business of innovation can end up make you feeling slightly jaded. We have a front-row seat to what is new and compelling, but it’s quite common to encounter company executives routinely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback